Tocofersolan
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Tocofersolan: From Vitamin E Deficiency to Amenorrhea
One-Sentence Summary
Tocofersolan is a water-soluble vitamin E derivative (TPGS), publicly known to be used for vitamin E deficiency associated with fat malabsorption (evidence pack contains no confirmed original indication data). The TxGNN model predicts it may be effective for Amenorrhea, but this prediction is currently supported by no clinical trials and no publications — the score alone is not sufficient evidence for action.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in evidence pack; publicly known use is vitamin E deficiency due to fat malabsorption/chronic cholestasis (unverified against source documents) |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L5 |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on known information, tocofersolan is a water-soluble tocopherol (vitamin E) ester used to correct vitamin E deficiency, and no verified original indication text is present in this evidence pack.
There is no established physiological pathway linking vitamin E supplementation to modulation of the hypothalamic-pituitary-ovarian axis or menstrual cycle regulation. The TxGNN model's link between tocofersolan and amenorrhea rests solely on a graph-based prediction score (0.993), with no mechanistic, clinical, or literature corroboration.
A second candidate in this evidence pack, acne (score 99.03%, rank 9278), follows the same pattern — a plausible-sounding antioxidant/sebum-modulation hypothesis, but with zero supporting trials or publications. Both predictions should be treated as hypothesis-generating signals only, not as evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Finland Market Information
Tocofersolan is not currently marketed in Finland (market status: Not Marketed, 0 authorizations on record). No product-level information is available.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA package insert warnings/contraindications are marked as a Blocking data gap — this must be resolved before any S1 safety review can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- Evidence level is L5 (model prediction only) with zero clinical trials or literature, and MOA plus TFDA warning/contraindication data are both missing (one flagged Blocking, one High severity) — there is currently no basis to advance past initial screening.
To proceed, the following is needed:
- TFDA package insert (warnings, contraindications) — Blocking gap, required before any safety pre-assessment (S1)
- Confirmed mechanism of action data from DrugBank — High-priority gap, needed to assess mechanistic plausibility for amenorrhea/acne
- Confirmation of the drug's original approved indication(s), currently absent from this evidence pack
- Any preclinical or mechanistic literature connecting vitamin E/TPGS pathways to reproductive endocrinology or dermatologic outcomes, to justify moving beyond L5
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.